New York State Common Retirement Fund Boosts Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

New York State Common Retirement Fund boosted its position in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 21.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,202,334 shares of the medical technology company’s stock after purchasing an additional 210,519 shares during the period. New York State Common Retirement Fund owned about 0.85% of Alphatec worth $11,037,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in ATEC. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in Alphatec by 11.3% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock valued at $16,280,000 after buying an additional 297,850 shares during the period. Barclays PLC grew its position in shares of Alphatec by 362.3% during the 3rd quarter. Barclays PLC now owns 170,546 shares of the medical technology company’s stock valued at $948,000 after acquiring an additional 133,653 shares during the period. Franklin Resources Inc. increased its stake in shares of Alphatec by 299.3% in the 3rd quarter. Franklin Resources Inc. now owns 64,450 shares of the medical technology company’s stock worth $343,000 after purchasing an additional 48,308 shares in the last quarter. AlphaCentric Advisors LLC purchased a new position in Alphatec during the third quarter valued at $2,057,000. Finally, Royce & Associates LP lifted its position in shares of Alphatec by 15.9% during the 3rd quarter. Royce & Associates LP now owns 1,212,286 shares of the medical technology company’s stock valued at $6,740,000 after buying an additional 165,954 shares in the last quarter. 66.35% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Patrick Miles sold 6,687 shares of Alphatec stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $12.00, for a total value of $80,244.00. Following the completion of the transaction, the chief executive officer now owns 5,501,715 shares in the company, valued at approximately $66,020,580. This trade represents a 0.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Scott Lish sold 27,453 shares of the business’s stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $11.49, for a total value of $315,434.97. Following the sale, the chief operating officer now directly owns 867,677 shares in the company, valued at $9,969,608.73. The trade was a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 222,376 shares of company stock valued at $2,557,148 in the last three months. Corporate insiders own 22.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Needham & Company LLC upped their price target on shares of Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. Barclays increased their price target on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 22nd. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Alphatec in a research note on Tuesday, January 14th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Alphatec has an average rating of “Moderate Buy” and a consensus target price of $17.56.

Alphatec Trading Up 1.4 %

Shares of ATEC opened at $10.76 on Tuesday. The stock has a market capitalization of $1.53 billion, a PE ratio of -8.41 and a beta of 1.43. The company’s fifty day moving average is $10.50 and its 200 day moving average is $8.30. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $15.41.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.